Furthermore, activation of TRPV-1 increases the release of several pro-inflammatory molecules, for example neuropeptide substance P (sP) and cytokines such as interleukin 6 (IL-6), exactly the molecules that have been implicated in the pathophysiological events associated with COVID-19. This evidence concerns the gene TFF2 and COVID-19.